Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.

@article{Ong2005AntiIgEI,
  title={Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.},
  author={Yee Ean Ong and Andrew N Menzies-Gow and Julia Barkans and Farid Benyahia and Tsen-Teng Ou and Sun Ying and Antony B. Kay},
  journal={The Journal of allergy and clinical immunology},
  year={2005},
  volume={116 3},
  pages={558-64}
}
BACKGROUND Anti-IgE (omalizumab) inhibited early and late asthmatic reactions and infiltration of inflammatory cells in asthmatic bronchial biopsies at baseline. The effect of chronic allergen exposure on these outcomes is unknown. Repeat allergen challenge in human skin represents a suitable model to address this question. OBJECTIVE To study the effect… CONTINUE READING